Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Info
    • Snapshot
    • Quote (Nasdaq)
    • Charts (Nasdaq)
    • Historical Data (Nasdaq)
    • Quote (TSX)
    • Charts (TSX)
    • Historical Data (TSX)
    • Analyst Coverage
  • Filings & Financials
    • Reports
    • SEC Filings
    • SEDAR Filings
    • Tax Information (PFIC)
  • Corporate Governance
  • FAQs
  • Email Alerts
  • IR Contacts
Aug 16, 2019

Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants

Aug 14, 2019

CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants

Aug 14, 2019

Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants

Aug 13, 2019

Oncolytics Biotech(R) Announces Public Offering of Common Shares and Warrants

Aug 13, 2019

Oncolytics Biotech(R) Reports 2019 Second Quarter Financial Results and Operational Highlights

Jul 23, 2019

Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R)

Jun 5, 2019

Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

Jun 5, 2019

Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA

May 29, 2019

Oncolytics Biotech(R) to Present at the 9th Annual LD Micro Invitational Investor Conference

May 16, 2019

Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting

RSS
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...53
    © 2021 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap